Last reviewed · How we verify

Ropivacain

University Hospital, Basel, Switzerland · FDA-approved active Small molecule Quality 19/100

At a glance

Generic nameRopivacain
SponsorUniversity Hospital, Basel, Switzerland
TargetPotassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
ModalitySmall molecule
Therapeutic areaPain
PhaseFDA-approved

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results